Mini-Mental State Examination: Optimal Cut-Off Levels for Mild and Severe Cognitive Impairment (2024)

  • Journal List
  • Geriatrics (Basel)
  • PMC9844353

As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice

Mini-Mental State Examination: Optimal Cut-Off Levels for Mild and Severe Cognitive Impairment (1)

Link to Publisher's site

Geriatrics (Basel). 2023 Feb; 8(1): 12.

Published online 2023 Jan 12. doi:10.3390/geriatrics8010012

PMCID: PMC9844353

PMID: 36648917

Francesco Salis,* Diego Costaggiu, and Antonella Mandas

Virginia Boccardi, Academic Editor

Author information Article notes Copyright and License information PMC Disclaimer

Associated Data

Data Availability Statement

Abstract

Considering the need to intercept neurocognitive damage as soon as possible, it would be useful to extend cognitive test screening throughout the population. Here, we propose differential cut-off levels that can be used to identify mild and severe cognitive impairment with a simple and widely used first-level neurocognitive screening test: the Mini-Mental State Examination (MMSE). We studied a population of 262 patients referred for cognitive impairment testing using the MMSE and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a neuropsychological battery. The sample consisted of 262 participants with mean age 73.8 years (60–87), of whom 154 (58.8%) women. No significant gender-related differences in cognitive ability were identified. The two tests (MMSE and RBANS) showed a moderate correlation in identifying cognitive deficit. We used RBANS as a categorial variable to identify different degrees of cognitive impairment. Youden’s J indexes were used to consider the better sensitivity/specificity balance in the 24-point cut-off score for severe cognitive deficit, 29.7-point score for mild cognitive deficit, and 26.1-point score for both mild and severe cognitive deficit. The study shows that the MMSE does not identify early cognitive impairment. Though different cut-offs are needed to discriminate different impairment degrees, the 26.1-point score seems to be preferable to the others.

Keywords: dementia, memory, mild cognitive impairment (MCI), Mini-Mental State Examination (MMSE), Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), screening

1. Introduction

The 2019 World Alzheimer Report [1] underlines the fact that the current population affected by neurocognitive disorders (including mild cognitive impairment, which represents a 3–4 relative risk of dementia), which amounts to around 50 million people, is destined by 2050 to reach more than triple that figure (152 million) due to the increase in the average global median age. The ageing of the population inevitably leads to an increase in geriatric syndromes, such as anemia [2], neurocognitive disorders [1], frailty, and polypharmacotherapy [3].

A report published in 2019 [4] showed cautious optimism about the possibility of having, in the near future, a therapy able to slow the progression of Alzheimer’s disease but also lamented the lack of tools capable of detecting impairment in time for the therapy to work.

It therefore seems appropriate to focus on first-level neurocognitive tests in order to enable patients to seek help from health professionals before their neurocognitive status is impaired. Incidentally, it should be noted that other tools for the early identification of damage to central nervous system are available [5].

Several studies are to be found in the scientific literature, which refer to Mini-Mental State Examination (MMSE) and also Montreal Cognitive Assessment (MoCA), comparing their capacity to detect cognitive impairment. A 2016 meta-analysis [6] concluded that MoCA seems to be more sensitive and specific than MMSE for the detection of mild deterioration in people aged over 60. However, unlike MMSE, neither in clinical practice nor in the literature is MoCA widely present or employed. A 2019 meta-analysis [7] makes it clear that, despite the fact that MoCA and other tests seem to be more sensitive, MMSE is the most frequently used worldwide. One of the most widely discussed topics on MMSE is the interpretation of the cut-off score used to identify cognitive impairment. In the literature, it is debated as to which guarantees the best sensitivity/specificity ratio [8]. Nonetheless, the test can be used in patient follow-up to assess the effectiveness of any treatment [9,10,11].

Nevertheless, neuropsychological batteries aid the diagnosis of neurocognitive disorders. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is one of them. It offers the possibility of identifying different degrees of neurocognitive deficit and is also useful for characterizing neurocognitive disorders of different etiologies. For example, this battery is not only proven to have a sufficiently high accuracy diagnosis-wise [12], but it is also useful for detecting HIV-associated neurocognitive disorders [13,14]. The RBANS’ areas of application also extend to other causes of cognitive impairment, such as alcohol dependence [15], post-traumatic stress disorder [16], and progressive supranuclear palsy [17].

Given the need to intercept neurocognitive damage as soon as possible, the primary aim of the study was to understand MMSE’s accuracy in identifying cognitive impairment.

The secondary aim of the study was to identify MMSE’s cut-off levels offering the optimal sensitivity and specificity in identifying both mild and severe cognitive impairment.

2. Methods

  • -

    Design of the study

    We performed a cross-sectional study including subjects who were consecutively evaluated at the Geriatric Outpatient Service of Cagliari University Hospital between January and August 2019. The accuracy of MMSE was assessed in comparison with RBANS.

    Inclusion criteria: age ≥ 60 years and presenting with subjective cognitive impairment complaints.

    Exclusion criteria: age < 60 years; not previously subjected to MMSE and/or RBANS; not presenting with subjective cognitive impairment complaints; and consent not provided.

    A sum of 262 subjects met the inclusion criteria.

    The sample were subjected by trained geriatricians to the following:

    • RBANS

    First used as a diagnostic tool, RBANS [18,19] subsequently became a screening tool, which, unlike others, can draw a profile of the various cognitive domains. RBANS evaluates five cognitive domains (immediate memory, visuospatial/constructional abilities, language, attention, and delayed memory), each with an index score (RBANS-IS). The range of the five index scores’ sum is from 200 to 800. This sum is converted into the total scale index (RBANS-TIS). To avoid the influences of age differences, conversion tables are available. A RBANS-TIS (and also RBANS-IS) between 85 and 70 (1 Standard Deviation (SD) below the mean) indicates a probable deficit, while a score of <70 (2 SD below the mean) likely indicates cognitive impairment.

    • MMSE

MMSE [20,21] is a quick and simple screening tool used to evaluate five cognitive domains (orientation, immediate memory, attention, delayed memory, and language). The sum of the scores obtained for each of them gives a total score ranging from 0 to 30. To avoid the influences of age and schooling differences, conversion tables are available.

  • -

    Statistical analysis

Quantitative variables were expressed as means ± SD. The scores’ correlation was studied using Pearson’s correlation coefficient (r). MMSE’s internal consistency was studied using Cronbach’s alpha. MMSE’s performance was studied using the area under the receiver operating characteristic (ROC) curve (AUC). Youden’s J statistic was used to identify the optimal cut-off levels according to the sensitivity, specificity, and positive and negative likelihood ratios (+LR, −LR).

The results are reported, indicating p-values in reference to 95% confidence intervals.

MedCalc software (Version 19.5, Ostend, Belgium) was used for the statistical analysis.

3. Results

The study included 262 participants with subjective cognitive impairment complaints (age: 73.8 ± 5.8 years (range: 60–87); gender: 154 (58.8%) women, 108 (41.2%) men). The characteristics of the enrolled subjects are shown in Table 1. There were no significant gender-related differences in the MMSE (p = 0.26) and RBANS (p = 0.78) scores.

Table 1

Characteristics of the sample.

VariablesMinimumMaximumMeanSD
Age (years)608773.775.81
Years in school0188.044.49
RBANS total scale (corrected for age)4613177.2414.44
MMSE (corrected for age and years in school)14.73025.253.69
MMSE prientation3108.861.66
MMSE immediate memory132.980.19
MMSE attention054.331.25
MMSE delayed memory031.781.13
MMSE language497.941.11

Open in a separate window

MMSE, Mini-Mental State Examination; RBANS, Repeatable Battery for the Assessment of Neurocognitive Status; SD, standard deviation.

According to RBANS, 66 people (25.2%) had adequate cognitive abilities (RBANS ≥ 85). Of the other 196 subjects, 79 (30.15% of the sample) had severe deficit (RBANS < 70), while a large group (187 subjects, 71.4%) scored MMSE ≥24.

Pearson’s correlation coefficient (Figure 1) between the two tests was 0.49 (95% confidence interval (C.I.): 0.39–0.57; p < 0.0001).

Open in a separate window

Figure 1

Pearson’s correlation coefficient (RBANS vs. MMSE). MMSE, Mini-Mental State Examination; RBANS, Repeatable Battery for the Assessment of Neurocognitive Status.

We studied MMSE’s internal consistency using Cronbach’s alpha. The coefficient was 0.63 (95% lower confidence limit: 0.57), and the effect of the dropping variables ranged between 0.49 and 0.68 (Table 2).

Table 2

Cronbach’s alpha—dropping variables.

Variable DroppedAlphaChange
MMSE Orientation0.49−0.14
MMSE Immediate Memory0.670.04
MMSE Attention0.54−0.09
MMSE Delayed Memory0.54−0.09
MMSE Language0.56−0.07

Open in a separate window

MMSE, Mini-Mental State Examination.

RBANS was used as the “classification variable” to identify the presence (“1”) or absence (“0”) of cognitive impairment. The 85-point cut-off score was used to define mild deficit, and the 70-point cut-off score was used to define severe deficit.

For the first, we considered 0: RBANS ≥ 70 and 1: RBANS < 70. In this analysis (Figure 2), MMSE showed an AUC: 0.79 (standard error: 0.03, 95% C.I.: 0.74–0.84; p < 0.0001). Each cut-off score’s sensitivity, specificity, +LR, and −LR are shown in Table 3. Youden’s J index was 0.48 for the criterion of MMSE ≤ 24, with 63.3% sensitivity, 84.7% specificity, 4.14 +LR, and 0.43 −LR.

Open in a separate window

Figure 2

AUC (severe impairment). MMSE, Mini-Mental State Examination; AUC, area under the ROC curve.

Table 3

Criterion values and coordinates of the ROC curve (severe impairment).

CriterionSensitivity95% C.I.Specificity95% C.I.+LR−LR
<14.700.0–4.610098.0–100.01
≤153.80.8–10.710098.0–100.00.96
≤15.33.80.8–10.799.4597.0–100.06.950.97
≤18.924.0515.1–35.099.4597.0–100.044.010.76
≤1925.3216.2–36.498.9196.1–99.923.160.76
≤19.325.3216.2–36.498.3695.3–99.715.440.76
≤19.527.8518.3–39.198.3695.3–99.716.990.73
≤19.732.9122.7–44.497.8194.5–99.415.060.69
≤2035.4425.0–47.097.8194.5–99.416.220.66
≤20.135.4425.0–47.097.2793.7–99.112.970.66
≤21.141.7730.8–53.497.2793.7–99.115.290.6
≤21.441.7730.8–53.496.7293.0–98.812.740.6
≤21.543.0431.9–54.796.7293.0–98.813.130.59
≤21.943.0431.9–54.796.1792.3–98.411.250.59
≤2244.333.1–55.993.9989.5–97.07.370.59
≤22.244.333.1–55.993.4488.8–96.66.760.6
≤22.448.136.7–59.692.3587.5–95.86.290.56
≤22.753.1641.6–64.591.2686.2–94.96.080.51
≤22.954.4342.8–65.791.2686.2–94.96.230.5
≤23.254.4342.8–65.790.1684.9–94.15.530.51
≤23.355.744.1–66.988.5283.0–92.84.850.5
≤23.455.744.1–66.987.9882.4–92.34.630.5
≤23.658.2346.6–69.287.9882.4–92.34.840.47
≤23.760.7649.1–71.685.2579.3–90.04.120.46
≤2463.2951.7–73.984.778.7–89.64.140.43
≤24.263.2951.7–73.983.0676.8–88.23.740.44
≤24.364.5653.0–75.081.4275.0–86.83.470.44
≤24.465.8254.3–76.180.3373.8–85.83.350.43
≤24.567.0955.6–77.380.3373.8–85.83.410.41
≤24.768.3556.9–78.477.0570.3–82.92.980.41
≤24.968.3556.9–78.475.9669.1–82.02.840.42
≤2569.6258.2–79.573.7766.8–80.02.650.41
≤25.369.6258.2–79.570.4963.3–77.02.360.43
≤25.470.8959.6–80.670.4963.3–77.02.40.41
≤25.774.6863.6–83.867.7660.5–74.52.320.37
≤25.874.6863.6–83.867.2159.9–74.02.280.38
≤25.975.9565.0–84.965.0357.6–71.92.170.37
≤2677.2266.4–85.961.7554.3–68.82.020.37
≤26.177.2266.4–85.960.6653.2–67.81.960.38
≤26.278.4867.8–86.958.4751.0–65.71.890.37
≤26.378.4867.8–86.953.5546.0–60.91.690.4
≤26.481.0170.6–89.050.2742.8–57.71.630.38
≤26.783.5473.5–90.946.4539.1–54.01.560.35
≤26.884.8175.0–91.946.4539.1–54.01.580.33
≤26.984.8175.0–91.945.938.5–53.41.570.33
≤2786.0876.5–92.841.5334.3–49.01.470.34
≤27.386.0876.5–92.836.0729.1–43.51.350.39
≤27.491.1482.6–96.432.7926.0–40.11.360.27
≤27.794.9487.5–98.630.0523.5–37.31.360.17
≤28.494.9487.5–98.622.416.6–29.11.220.23
≤28.796.289.3–99.220.7715.1–27.41.210.18
≤2998.7393.1–100.020.2214.7–26.81.240.063
≤29.798.7393.1–100.019.1313.7–25.61.220.066
≤3010095.4–100.000.0–2.01

Open in a separate window

CI, confidence interval; +LR, positive likelihood ratio; −LR, negative likelihood ratio.

Then, we considered 0: RBANS ≥ 85 and 1: RBANS < 85 and ≥70. In this analysis (Figure 3), MMSE showed an AUC: 0.665 (standard error: 0.04; 95% C.I.: 0.59–0.73; p = 0.0001). Each cut-off score’s sensitivity, specificity, +LR, and −LR are shown in Table 4. Youden’s J index was 0.27 for the criterion of MMSE ≤ 29.7, with 90.6% sensitivity, 36.4% specificity, 1.42 + LR, and 0.26 − LR.

Open in a separate window

Figure 3

AUC (mild impairment). MMSE, Mini-Mental State Examination; AUC, area under the ROC curve.

Table 4

Criterion values and coordinates of the ROC curve (mild impairment).

CriterionSensitivity95% C.I.Specificity95% C.I.+LR−LR
<15.300.0–3.110094.6–100.01
≤21.95.982.4–11.910094.6–100.00.94
≤228.554.2–15.298.4891.8–100.05.640.93
≤22.411.116.1–18.398.4891.8–100.07.330.9
≤22.711.116.1–18.395.4587.3–99.12.440.93
≤2311.976.7–19.395.4587.3–99.12.630.92
≤23.211.976.7–19.393.9485.2–98.31.970.94
≤23.313.688.0–21.392.4283.2–97.51.810.93
≤24.120.5113.6–29.092.4283.2–97.52.710.86
≤24.220.5113.6–29.089.3979.4–95.61.930.89
≤24.424.7917.3–33.689.3979.4–95.62.340.84
≤24.727.3519.5–36.484.8573.9–92.51.810.86
≤24.928.2120.3–37.383.3372.1–91.41.690.86
≤2531.6223.3–40.983.3372.1–91.41.90.82
≤25.231.6223.3–40.981.8270.4–90.21.740.84
≤25.335.927.2–45.381.8270.4–90.21.970.78
≤25.737.6128.8–47.077.2765.3–86.71.650.81
≤25.837.6128.8–47.075.7663.6–85.51.550.82
≤26.147.8638.5–57.375.7663.6–85.51.970.69
≤26.248.7239.4–58.171.2158.7–81.71.690.72
≤26.353.8544.4–63.166.6754.0–77.81.620.69
≤26.457.2647.8–66.463.6450.9–75.11.570.67
≤26.760.6851.2–69.659.0946.3–71.01.480.67
≤26.961.5452.1–70.459.0946.3–71.01.50.65
≤2765.8156.5–74.354.5541.8–66.91.450.63
≤27.166.6757.4–75.154.5541.8–66.91.470.61
≤27.266.6757.4–75.153.0340.3–65.41.420.63
≤27.372.6563.6–80.551.5238.9–64.01.50.53
≤27.476.0767.3–83.548.4836.0–61.11.480.49
≤27.779.4971.0–86.446.9734.6–59.71.50.44
≤2881.272.9–87.843.9431.7–56.71.450.43
≤28.182.0573.9–88.542.4230.3–55.21.430.42
≤28.383.7675.8–89.942.4230.3–55.21.450.38
≤28.485.4777.8–91.336.3624.9–49.11.340.4
≤29.790.683.8–95.236.3624.9–49.11.420.26
≤3010096.9–100.000.0–5.41

Open in a separate window

CI, confidence interval; +LR, positive likelihood ratio; −LR, negative likelihood ratio.

Finally, we considered 0: RBANS ≥ 85 and 1: RBANS < 85. In this analysis (Figure 4), MMSE showed an AUC: 0.74 (standard error: 0.03; 95% C.I.: 0.68–0.79; p < 0.0001). Each cut-off score’s sensitivity, specificity, +LR, and −LR are shown in Table 5. Youden’s J index was 0.35 for the criterion of MMSE ≤ 26.1, with 59.69% sensitivity, 75.76% specificity, 2.46 + LR, and 0.53 − LR.

Open in a separate window

Figure 4

AUC (mild and severe impairment). MMSE, Mini-Mental State Examination; AUC, area under the ROC curve.

Table 5

Criterion values and coordinates of the ROC curve (mild and severe impairment).

CriterionSensitivity95% C.I.Specificity95% C.I.+LR−LR
<14.700.0–1.910094.6–100.01
≤21.920.9215.4–27.310094.6–100.00.79
≤2222.9617.3–29.598.4891.8–100.015.150.78
≤22.426.0220.0–32.898.4891.8–100.017.170.75
≤22.728.0621.9–34.995.4587.3–99.16.170.75
≤2329.0822.8–36.095.4587.3–99.16.40.74
≤23.229.0822.8–36.093.9485.2–98.34.80.75
≤23.330.6124.2–37.692.4283.2–97.54.040.75
≤24.137.7630.9–44.992.4283.2–97.54.980.67
≤24.237.7630.9–44.989.3979.4–95.63.560.7
≤24.541.8434.8–49.189.3979.4–95.63.940.65
≤24.743.8836.8–51.184.8573.9–92.52.90.66
≤24.944.3937.3–51.683.3372.1–91.42.660.67
≤2546.9439.8–54.283.3372.1–91.42.820.64
≤25.246.9439.8–54.281.8270.4–90.22.580.65
≤25.45042.8–57.281.8270.4–90.22.750.61
≤25.752.5545.3–59.777.2765.3–86.72.310.61
≤25.852.5545.3–59.775.7663.6–85.52.170.63
≤26.159.6952.5–66.675.7663.6–85.52.460.53
≤26.260.7153.5–67.671.2158.7–81.72.110.55
≤26.363.7856.6–70.566.6754.0–77.81.910.54
≤26.466.8459.8–73.463.6450.9–75.11.840.52
≤26.769.963.0–76.259.0946.3–71.01.710.51
≤26.970.9264.0–77.259.0946.3–71.01.730.49
≤2773.9867.2–80.054.5541.8–66.91.630.48
≤27.174.4967.8–80.454.5541.8–66.91.640.47
≤27.274.4967.8–80.453.0340.3–65.41.590.48
≤27.378.0671.6–83.651.5238.9–64.01.610.43
≤27.482.1476.1–87.248.4836.0–61.11.590.37
≤27.785.7180.0–90.346.9734.6–59.71.620.3
≤2886.7381.2–91.143.9431.7–56.71.550.3
≤28.187.2481.7–91.642.4230.3–55.21.520.3
≤28.388.2782.9–92.442.4230.3–55.21.530.28
≤28.489.2984.1–93.236.3624.9–49.11.40.29
≤29.793.8889.5–96.836.3624.9–49.11.480.17
≤3010098.1–100.000.0–5.41

Open in a separate window

CI, confidence interval; +LR, positive likelihood ratio; −LR, negative likelihood ratio.

The threshold was also studied using the different subsets of the sample after dividing it into quartiles according to the variable of “age” (Table 6). In the 1st quartile (≤70 years), Youden’s J index was 0.36 for the criterion of MMSE ≤ 29.7, with 88.89% sensitivity and 46.88% specificity (p = 0.0005). In the 2nd quartile (71–74), Youden’s J index was 0.36 for the criterion of MMSE ≤ 23.7, with 41.46% sensitivity and 94.44% specificity (p = 0.0058). In the 3rd quartile (75–78), Youden’s J index was 0.67 for the criterion of MMSE ≤ 26, with 67.24% sensitivity and 100% specificity (p < 0.0001). Finally, in the 4th quartile (≥79), the AUC showed non-significant results (p = 0.0809).

Table 6

Youden’s indexes of the subsets.

QuartileCriterionJSensitivity95% C.I.Specificity95% C.I.AUCp
1≤29.70.3688.8975.9–96.346.8829.1–65.30.710.0005
2≤23.70.3641.4626.3–57.994.4472.7–99.90.690.0058
3≤260.6767.2453.7–79.0100.0066.4–100.00.84<0.0001
4≤280.4992.3181.5–95.757.1418.4–90.10.720.0809

Open in a separate window

CI, confidence interval; AUC, area under the ROC curve.

4. Discussion

In this study, we collected and examined data from a sample of 262 subjects referred for neurocognitive function assessment. The aims of the study were to analyze MMSE’s accuracy in identifying cognitive impairment by comparing it with a more sensitive neuropsychological battery (RBANS) and to describe cut-off levels offering the optimal sensitivity and specificity in identifying different degrees of cognitive impairment due to the need to identify a greater number of patients with cognitive impairment [4]. Given the close relationship between cognitive impairment and impairment in other domains [22], the widespread use of MMSE, in particular, requires improvements in its use as a first-level screening tool.

The correlation between the two tests was moderate (r = 0.49), and MMSE, according to the most common 24-point cut-off score, only identified deficiency in less than 30% of the sample, while RBANS, on the contrary, showed only 25.2% of the sample to have adequate cognitive abilities. Moreover, MMSE’s internal consistency was questionable (Cronbach’s alpha: 0.63).

In order to discriminate mild from severe cognitive impairment, we considered the 85-point and the 70-point RBANS cut-off scores, respectively. We obtained a first AUC study to evaluate which MMSE score could offer the better sensitivity and specificity in identifying advanced cognitive deficit. The 24-point cut-off score demonstrated a good specificity and an acceptable sensitivity. The second AUC was studied to evaluate which MMSE score is better in identifying a milder cognitive deficit. The analysis of Youden’s J demonstrated that the better sensitivity/specificity balance was exhibited by the 29.7-point cut-off. Through the analysis, it emerged that even the consideration of lower scores leads to a poor increase in the specificity, with lowered sensitivity. This aspect emphasizes the poor capacity of MMSE for identifying people with low-degree cognitive impairment, because the 29.7-point cut-off has no clinical significance, owing to the fact that MMSE scores range from 0 to 30. For this reason, our final analysis was conducted considering the “impaired” subjects with both mild and severe impairment. The 26.1-point cut-off seemed to show an adequate performance in this sense. This result follows in the literature’s footsteps, which firstly focused on the 24-point cutoff [8,23,24], while more recent studies considered higher scores as the optimal cut-off, in particular the 26-point cut-off [25,26], though MMSE remains less sensitive than other tools, even though it is widely used [7].

The study of the thresholds of the four subsets according to age showed that people between 71 and 78 years old would benefit more from MMSE, while for people younger than 70, we found that 29.7 points is the best cut-off level (with no clinical significance, as stated before), and for people older than 78, we did not even find a significant cut-off level. These data confirm that MMSE is not the ideal tool for detecting an early deficit typical of younger people and that, paradoxically, it loses its meaning with increasing age, since aging is related to a “phenotypic manifestation” of NCD, making the screening tests less useful.

5. Conclusions

Our analysis showed that MMSE, though widely administered, is not able to identify early cognitive deficit, especially when considering the 24-point cut-off score. Different cut-offs are needed to discriminate between different impairment degrees, and the 26.1-point score seems to be preferable to the others, especially for people aged between 71 and 78.

The limitations of this study include the fact that it is monocentric and enrolled a relatively small sample. Further studies with longitudinal monitoring could confirm the suitability of our hypothesis and encourage the development of more sensitive first-level cognitive screening tests.

Abbreviations

AUC: area under the ROC curve; CI: confidence interval; +LR: positive likelihood ratio; −LR: negative likelihood ratio; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; RBANS: Repeatable Battery for the Assessment of Neuropsychological Status; RBANS-IS: RBANS index score; RBANS-TIS: RBANS total scale index; ROC: receiver operating characteristic; SD: standard deviation.

Funding Statement

This research received no external funding.

Author Contributions

F.S., D.C. and A.M. designed and performed the study; F.S. wrote the manuscript with support from A.M.; A.M. supervised the findings of the work. All authors approved the submitted version. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

All procedures involving human participants were performed in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The Research Ethics Committee of the University of Cagliari approved this study (certification NP/2022/1382). Participation was voluntary, and informed consent to participate and for the publication of the study was obtained from all the participants before data collection.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data and materials used and/or analyzed during the current study are not publicly available. They are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors have no conflict of interest to declare.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

1. Alzheimer’s Disease International . World Alzheimer Report 2019: Attitudes to Dementia. Alzheimer’s Disease International; London, UK: 2019. [Google Scholar]

2. Salis F., Locci G., Mura B., Mandas A. Anemia in Elderly Patients—The Impact of Hemoglobin Cut-Off Levels on Geriatric Domains. Diagnostics. 2023;13:191. doi:10.3390/diagnostics13020191. [CrossRef] [Google Scholar]

3. Loddo S., Salis F., Rundeddu S., Serchisu L., Peralta M.M., Mandas A. Nutritional Status and Potentially Inappropriate Medications in Elderly. J. Clin. Med. 2022;11:3465. doi:10.3390/jcm11123465. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Hlavka J.P., Mattke S., Liu J.L. Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer’s Treatment. Rand Health Q. 2019;8:2. [PMC free article] [PubMed] [Google Scholar]

5. Pani A., Mandas A., Diaz G., Abete C., Cocco P.L., Angius F., Brundu A., Muçaka N., Pais M.E., Saba A., et al. Accumulation of neutral lipids in peripheral blood mononuclear cells as a distinctive trait of Alzheimer patients and asymptomatic subjects at risk of disease. BMC Med. 2009;7:66. doi:10.1186/1741-7015-7-66. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Ciesielska N., Sokołowski R., Mazur E., Podhorecka M., Polak-Szabela A., Kędziora-Kornatowska K. Is the Montreal Cognitive Assessment (MoCA) test better suited than the Mini-Mental State Examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr. Polska. 2016;50:1039–1052. doi:10.12740/PP/45368. [PubMed] [CrossRef] [Google Scholar]

7. Breton A., Casey D., Arnaoutoglou N.A. Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. Int. J. Geriatr. Psychiatry. 2019;34:233–242. doi:10.1002/gps.5016. [PubMed] [CrossRef] [Google Scholar]

8. Creavin S.T., Wisniewski S., Noel-Storr A.H., Trevelyan C.M., Hampton T., Rayment D., Thom V.M., Nash K.J., Elhamoui H., Milligan R., et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst. Rev. 2016;13:CD011145. doi:10.1002/14651858.CD011145.pub2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Pimouguet C., Le Goff M., Wittwer J., Dartigues J.-F., Helmer C. Benefits of Occupational Therapy in Dementia Patients: Findings from a Real-World Observational Study. J. Alzheimer’s Dis. 2017;56:509–517. doi:10.3233/JAD-160820. [PubMed] [CrossRef] [Google Scholar]

10. McShane R., Westby M.J., Roberts E., Minakaran N., Schneider L., Farrimond L.E., Maayan N., Ware J., Debarros J. Memantine for dementia. Cochrane Database Syst. Rev. 2019;3:CD003154. doi:10.1002/14651858.CD003154.pub6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Fonte C., Smania N., Pedrinolla A., Munari D., Gandolfi M., Picelli A., Varalta V., Benetti M.V., Brugnera A., Federico A., et al. Comparison between physical and cognitive treatment in patients with MCI and Alzheimer’s disease. Aging. 2019;11:3138–3155. doi:10.18632/aging.101970. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

12. Shura R.D., Brearly T.W., Rowland J.A., Martindale S.L., Miskey H.M., Duff K. RBANS Validity Indices: A Systematic Review and Meta-Analysis. Neuropsychol. Rev. 2018;28:269–284. doi:10.1007/s11065-018-9377-5. [PubMed] [CrossRef] [Google Scholar]

13. Costaggiu D., Pinna E., Serchisu L., Barcellona D., Piano P., Ortu F., Marongiu F., Mandas A. The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders. AIDS Care. 2020;33:357–363. doi:10.1080/09540121.2020.1742859. [PubMed] [CrossRef] [Google Scholar]

14. Costaggiu L.S.D., Serchisu L., Abete C., Pinna E., Vascellari S., Ortu F., Manconi P.E., Pani A., Mandas A. Determination of Neutral Lipid and Cluster Formation for Screening Neurocognitive Impairment in Human Immunodeficiency Virus Patients. J. AIDS Clin. Res. 2015;6:517. doi:10.4172/2155-6113.1000517. [CrossRef] [Google Scholar]

15. Cao H., Hou C., Huang S., Zhou X., Yang J., Bin Xu J., Cao X., Li Z., Zhang W., Zhang M., et al. The Evaluation of Cognitive Impairment in Alcohol-Dependent Patients through RBANS Combined with ERPs. Front. Psychiatry. 2021;11:598835. doi:10.3389/fpsyt.2020.598835. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Hantke N. Posttraumatic Stress Disorder-Associated Cognitive Deficits on the Repeatable Battery for the Assessment of Neuropsychological Status in a Veteran Population. Fed. Pract. 2021;38:28–34. doi:10.12788/fp.0083. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Duff K., McDermott D., Luong D., Randolph C., Boxer A.L. Cognitive deficits in progressive supranuclear palsy on the Repeatable Battery for the Assessment of Neuropsychological Status. J. Clin. Exp. Neuropsychol. 2019;41:469–475. doi:10.1080/13803395.2019.1572073. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Randolph C., Tierney M.C., Mohr E., Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity. J. Clin. Exp. Neuropsychol. 1998;20:310–319. doi:10.1076/jcen.20.3.310.823. [PubMed] [CrossRef] [Google Scholar]

19. Ponteri M., Pioli R., Padovani A., Tunesi S., De Girolamo G. RBANS: Repeatable Battery for the Assessment of Neuropsychological Status (Italian Adaptation) Giunti O.S.; Firenze, Italy: 2007. [Google Scholar]

20. Folstein M.F., Folstein S.E., McHugh P.R. “Mini-Mental State”. A Practical Method for Grading the Cognitive State of Patients for the Clinician. J. Psychiatr. Res. 1975;12:189–198. doi:10.1016/0022-3956(75)90026-6. [PubMed] [CrossRef] [Google Scholar]

21. Measso G., Cavarzeran F., Zappalà G., Lebowitz B.D., Crook T.H., Pirozzolo F.J., Amaducci L.A., Massari D.C., Grigoletto F. The mini-mental state examination: Normative study of an Italian random sample. Dev. Neuropsychol. 1993;9:77–85. doi:10.1080/87565649109540545. [PubMed] [CrossRef] [Google Scholar]

22. Salis F., Loddo S., Zanda F., Peralta M.M., Serchisu L., Mandas A. Comprehensive Geriatric Assessment: Application and correlations in a real-life cross-sectional study. Front. Med. 2022;9:984046. doi:10.3389/fmed.2022.984046. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Sakurai R., Kim Y., Inagaki H., Tokumaru A.M., Sakurai K., Shimoji K., Kitamura A., Watanabe Y., Shinkai S., Awata S. MMSE Cutoff Discriminates Hippocampal Atrophy: Neural Evidence for the Cutoff of 24 Points. J. Am. Geriatr. Soc. 2021;69:839–841. doi:10.1111/jgs.17010. [PubMed] [CrossRef] [Google Scholar]

24. Patnode C.D., Perdue L.A., Rossom R.C., Rushkin M.C., Redmond N., Thomas R.G., Lin J.S. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force [Internet] Agency for Healthcare Research and Quality; Rockville, MD, USA: 2020. Report No.: 19-05257-EF-1. [PubMed] [Google Scholar]

25. Kvitting A.S., Fällman K., Wressle E., Marcusson J., Ot E.W., Marcusson J. Age-Normative MMSE Data for Older Persons Aged 85 to 93 in a Longitudinal Swedish Cohort. J. Am. Geriatr. Soc. 2018;67:534–538. doi:10.1111/jgs.15694. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Chun C.T., Seward K., Patterson A., Melton A., MacDonald-Wicks L. Evaluation of Available Cognitive Tools Used to Measure Mild Cognitive Decline: A Scoping Review. Nutrients. 2021;13:3974. doi:10.3390/nu13113974. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Articles from Geriatrics are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

Mini-Mental State Examination: Optimal Cut-Off Levels for Mild and Severe Cognitive Impairment (2024)

FAQs

Mini-Mental State Examination: Optimal Cut-Off Levels for Mild and Severe Cognitive Impairment? ›

Below 25, scores can indicate severe (≤9 points), moderate (10–20 points), or mild (21–24 points) cognitive impairment. For the MMSE, test and retest reliability has been examined in many studies.

What is the MMSE cutoff for mild cognitive impairment? ›

Interpretations. Any score of 24 or more (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10–18 points) or mild (19–23 points) cognitive impairment.

What are the cut-off values for mild cognitive impairment? ›

Youden's J indexes were used to consider the better sensitivity/specificity balance in the 24-point cut-off score for severe cognitive deficit, 29.7-point score for mild cognitive deficit, and 26.1-point score for both mild and severe cognitive deficit.

What is the cutoff score for mild cognitive impairment? ›

What are the severity levels for the MoCA?
  • Normal Cognitive performance 26 and above.
  • Mild impairment 18-25.
  • Moderate impairment 10-17.
  • Severe impairment 0-9.

What is a normal score on the mini mental status exam? ›

How is the MMSE scored? The top score for the MMSE is 30. A score of 25 or higher is said to be normal. A score of below 24 could mean cognitive impairment.

What is a bad score on a dementia test? ›

A perfect score is 30 points; a score of 24 is the recommended,4 and most frequently used,2 cutpoint for dementia; a score of 23 or lower indicates dementia. A cutoff score for lesser forms of impairment, eg, mild cognitive impairment, has not been established or implemented with any consistency.

What is the IQ score for mild cognitive impairment? ›

The measured IQ for persons with mild ID is between 50–55 and 70 (based on population mean of 100; 1 standard deviation of 15, and margin of measurement error of ±5) (8,10,13-16). Persons with mild ID have difficulty in the acquisition and comprehension of complex language and academic skills (10,13,15,16).

What are the 4 levels of cognitive impairment? ›

The four cognitive severity stages spanning normal aging to dementia are:
  • No Cognitive Impairment (NCI)
  • Subjective Cognitive Impairment (SCI)
  • Mild Cognitive Impairment (MCI)
  • Dementia.

What is severe cognitive impairment? ›

Problems with a person's ability to think, learn, remember, use judgement, and make decisions. Signs of cognitive impairment include memory loss and trouble concentrating, completing tasks, understanding, remembering, following instructions, and solving problems.

How bad is mild cognitive impairment? ›

MCI may include problems with memory, language or judgment. People with MCI may be aware that their memory or mental function has "slipped." Family and close friends also may notice changes. But these changes aren't bad enough to impact daily life or affect usual activities.

What is the criteria for mild cognitive impairment? ›

Symptoms associated with MCI lie in the space between what are considered normal age-related changes and dementia. Signs of MCI include losing things often, forgetting to go to important events or appointments, and having more trouble coming up with words than other people of the same age.

What is the CDR score for mild cognitive impairment? ›

Clinical Dementia Rating (CDR)

Ratings are assigned on a 0–5 point scale, (0 = absent; 0.5 = questionable; 1= present, but mild; 2 = moderate; 3 = severe; 4 = profound; 5 = terminal). A global summary score is obtained, leading to the use of the CDR for grouping patients on severity of dementia.

What is a bad cognitive score? ›

Interpreting the Results
InterpretationScore range
Normal cognition26-30 points
Mild cognitive impairment18-25 points
Moderate cognitive impairment10-17 points
Severe cognitive impairmentUnder 10 points

What does a score of 22 mean on the mini-mental state exam? ›

What Does MMSE Scoring Mean?
ScoreDegree of Impairment
25-30Clinically significant but mild impairments may be present but can be considered within the "normal" range
20-25Mild cognitive impairments or possible early-stage to mild dementia
10-20Clear impairments, possibly indicating middle-stage to moderate dementia
1 more row
Feb 14, 2024

What is an abnormal mini-mental status exam? ›

It is an 11-question measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall, and language. The maximum score is 30. A score of 23 or lower is indicative of cognitive impairment.

How accurate is the mini-mental status exam? ›

In a sub-analysis of 88 people with mild Alzheimer's scoring >20 on the MMSE, Kalbe and colleagues [25] found that the MMSE had a sensitivity of 92 % and a specificity of 86 % (PPV = 85.2 %, NPV = 92.2 %) which again would imply “good” clinical utility for case-finding (CUI + = 0.781) and screening (CUI− = 0.796).

What is the clinical dementia rating for mild cognitive impairment? ›

Memory Changes with Aging and Dementia

Ratings are assigned on a 0–5 point scale, (0 = absent; 0.5 = questionable; 1= present, but mild; 2 = moderate; 3 = severe; 4 = profound; 5 = terminal). A global summary score is obtained, leading to the use of the CDR for grouping patients on severity of dementia.

What is the threshold for MMSE? ›

MMSE score, for example, denotes the severity of cognitive impairment as follows: mild Alzheimer's disease: MMSE 21–26, moderate Alzheimer's disease: MMSE 10–20, moderately severe Alzheimer's disease: MMSE 10–14, severe Alzheimer's disease: MMSE less than 10.

What is the best assessment for mild cognitive impairment? ›

Health care providers often use a brief test such as the Short Test of Mental Status, the Montreal Cognitive Assessment (MoCA) or the Mini-Mental State Examination (MMSE). More detailed testing may help determine the degree memory is impaired.

What is the test for mild cognitive impairment? ›

Commonly used tests include: Montreal Cognitive Assessment (MoCA) test. This test takes about 15 minutes. It includes memorizing a short list of words, copying a drawing of a shape or object, and looking at pictures of animals and saying which animals you see.

References

Top Articles
Latest Posts
Article information

Author: Eusebia Nader

Last Updated:

Views: 6001

Rating: 5 / 5 (60 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Eusebia Nader

Birthday: 1994-11-11

Address: Apt. 721 977 Ebert Meadows, Jereville, GA 73618-6603

Phone: +2316203969400

Job: International Farming Consultant

Hobby: Reading, Photography, Shooting, Singing, Magic, Kayaking, Mushroom hunting

Introduction: My name is Eusebia Nader, I am a encouraging, brainy, lively, nice, famous, healthy, clever person who loves writing and wants to share my knowledge and understanding with you.